Auburn University

Altimmune, Inc.

Svk Laboratories, Inc.

Tng Pharmaceuticals, Inc.

Gnt Pharmaceuticals, Inc.

Kent R Van Kampen

De-Chu C Tang

Henry J Baker

Serge Martinod

Haroldo E Toro

Tatiana I Samoylova

Nancy R Cox

Allan E David

M Scot Roberts

Stephen Ditchkoff

Lowell R Smalley

Prachi Sangle

Aime K Johnson

Harold Toro

Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are vaccine compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or vaccine compositions. Further disclosed are methods for the preparation of a fusion protein composition.

Horn fly vaccine compositions and methods of making same

Hornfly vaccine methods

Therapeutic or prophylactic compositions providing an active agent, such as an antigen or a vector that contains and expresses an antigen, encapsulated in or incorporated into a biodegradable polymeric particle are provided. The compositions can also provide an active agent that is not encapsulated in or incorporated into the biodegradable polymeric particle in order to provide an initial or prime delivery of the active agent. Particles or composites providing an active agent encapsulated by a first and second polymer are also provided, wherein polymers are distributed in a gradient from a core of the composite to a surface of the composite, and configured to provide a delayed release of the active agent by a period of 7 days to 6 months. Methods of producing composites are also provided. Pharmaceutical formulations providing a single dose composition are also provided, along with methods for administering the pharmaceutical compositions to a subject in need thereof a therapeutically effective amount of an active agent are provided.

Biodegradable polymeric particles encapsulating an active agent, pharmaceutical compositions and uses thereof

The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens.

Immunization of avians by administration of non-replicating vectored vaccines

Methods and compositions for treating and preventing osteoporosis are disclosed. Osteoporosis is prevented and treated by administering an effective amount of a composition to a patient. The composition may be prepared from New Zealand green-lipped mussel () and may comprise one or more proteins, amino acids, minerals, sterol esters, sterols, polar lipids, triglycerides, fats, lipids, fatty acids, and polyunsaturated fatty acids (PUFAs) derived from the mussel. The active ingredients in the composition include one or more of an octadecatetraenoic acid (SDA), an eicosatetraenoic acid (ETA), an eicosapentaenoic acid (EPA), and a docosahexaenoic acid (DHA).

Methods and compositions for preventing and treating osteoporosis

Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines.

Zona pellucida binding peptides for species specific immunocontraception of animals

Growing community of inventors

Payson, UT, United States of America

Kent R Van Kampen